Founded in the year 2014 by Sujata Chaudhri and located in the National Capital Region (NCR) in India, our firm provides advisory, litigation and enforcement, and prosecution services in all areas of intellectual property law.
The Delhi High Court has handed down an important decision in Alkem Laboratories Ltd. v. Prevego Healthcare & Research Pvt. Ltd. , observing that device marks cannot automatically grant protection over the word or letters comprised therein, unless shown to have acquired secondary meaning. The court held that a registration for a device of the mark ‘A TO Z’ will not offer protection against use of the marks “A TO Z” or “AZ”, since these would be inherently descriptive. The
Semaglutide is the rare drug that sits at the intersection of science, culture and capital. The Delhi High Court’s semaglutide order in CS(COMM) 565/2025 Novo Nordisk v Dr Reddy’s shows how Indian courts will police the outer edge of that capital: the extra years companies try to add through follow‑on patents. Novo’s enforcement hinged on a later “species” patent, IN262697, claiming semaglutide as a specific GLP‑1 analogue. An older “genus” patent, IN275964, had already cl
The Sustainable Harnessing and Advancement of Nuclear Energy for Transforming India Act, 2025 (SHANTI Act) fundamentally transforms India's nuclear patent landscape from categorical prohibition to conditional authorization. The Legacy Framework (Section 20(1) of the Atomic Energy Act, 1962) For over five decades, Section 20(1) imposed an across-the-board prohibition on patents for inventions in the atomic energy field. This encompassed reactor technologies, uranium enrichmen
